news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

On July 4, 2024, the International Cooperation Department of the China Securities Regulatory Commission issued a notice onBeijing Kangleweishi Biotechnology Co., Ltd.Notice of Registration of Overseas Issuance and Listing(Guohehan [2024] No. 1383).The details of the filing notice are as follows:

Beijing Kangleweishi Biotechnology Co., Ltd.:

We have received the filing materials for your company's overseas issuance and listing. In accordance with the Securities Law of the People's Republic of China and the Trial Measures for the Administration of Overseas Securities Issuance and Listing by Domestic Enterprises, we hereby notify you of the filing matters as follows:

1. Your company intends to issue no more than 107,693,800 overseas listed common shares and list them on the Hong Kong Stock Exchange.

2. From the date of issuance of this filing notice to the completion of this overseas issuance and listing, if your company encounters any major event, you should report it through the China Securities Regulatory Commission's filing management information system in accordance with the relevant regulations on overseas issuance and listing of domestic enterprises.

3. Within 15 working days after the completion of your company's overseas issuance and listing, you should report the issuance and listing situation through the China Securities Regulatory Commission's filing management information system. Your company should strictly abide by relevant domestic and foreign laws, regulations and rules during the overseas issuance and listing process.